114 related articles for article (PubMed ID: 12708485)
1. A novel carbazole topoisomerase II poison, ER-37328: potent tumoricidal activity against human solid tumors in vitro and in vivo.
Nakamura K; Uenaka T; Nagasu T; Sugumi H; Yamaguchi A; Kotake Y; Okada T; Kamata J; Niijima J; Taniguchi T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
Cancer Sci; 2003 Jan; 94(1):119-24. PubMed ID: 12708485
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
Nakamura K; Sugumi H; Yamaguchi A; Uenaka T; Kotake Y; Okada T; Kamata J; Niijima J; Nagasu T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
Mol Cancer Ther; 2002 Jan; 1(3):169-75. PubMed ID: 12467211
[TBL] [Abstract][Full Text] [Related]
3. Effects of ER-37328 on primary tumor, liver metastasis, and life span in a murine colon 38 orthotopic transplantation model.
Nakamura K; Taniguchi T; Funahashi Y; Yoshimatsu K
Mol Cancer Ther; 2003 Jan; 2(1):59-64. PubMed ID: 12533673
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Utsugi T; Aoyagi K; Asao T; Okazaki S; Aoyagi Y; Sano M; Wierzba K; Yamada Y
Jpn J Cancer Res; 1997 Oct; 88(10):992-1002. PubMed ID: 9414662
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II.
Mistry P; Stewart AJ; Dangerfield W; Baker M; Liddle C; Bootle D; Kofler B; Laurie D; Denny WA; Baguley B; Charlton PA
Anticancer Drugs; 2002 Jan; 13(1):15-28. PubMed ID: 11914637
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of novel pyrimido-acridone, -phenoxadine, and -carbazole as topoisomerase II inhibitors.
Kamata J; Okada T; Kotake Y; Niijima J; Nakamura K; Uenaka T; Yamaguchi A; Tsukahara K; Nagasu T; Koyanagi N; Kitoh K; Yoshimatsu K; Yoshino H; Sugumi H
Chem Pharm Bull (Tokyo); 2004 Sep; 52(9):1071-81. PubMed ID: 15340192
[TBL] [Abstract][Full Text] [Related]
8. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
[TBL] [Abstract][Full Text] [Related]
9. Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Whitacre CM; Zborowska E; Willson JK; Berger NA
Clin Cancer Res; 1999 Mar; 5(3):665-72. PubMed ID: 10100720
[TBL] [Abstract][Full Text] [Related]
10. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
[TBL] [Abstract][Full Text] [Related]
11. Tirapazamine: a hypoxia-activated topoisomerase II poison.
Peters KB; Brown JM
Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
Bridewell DJ; Finlay GJ; Baguley BC
Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
[TBL] [Abstract][Full Text] [Related]
13. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II.
Zhu H; Huang M; Yang F; Chen Y; Miao ZH; Qian XH; Xu YF; Qin YX; Luo HB; Shen X; Geng MY; Cai YJ; Ding J
Mol Cancer Ther; 2007 Feb; 6(2):484-95. PubMed ID: 17308047
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors.
Dong YB; Yang HL; Elliott MJ; McMasters KM
Cancer Res; 2002 Mar; 62(6):1776-83. PubMed ID: 11912154
[TBL] [Abstract][Full Text] [Related]
15. MFTZ-1, an actinomycetes subspecies derived antitumor macrolide, functions as a novel topoisomerase II poison.
Xie CY; Zhu H; Lin LP; Miao ZH; Geng MY; Cai YJ; Chen Y; Zhao HJ; Luo HB; Zhang XW; Fan LM; Shen YM; Ding J
Mol Cancer Ther; 2007 Nov; 6(11):3059-70. PubMed ID: 18025289
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo.
Arcamone F; Animati F; Berettoni M; Bigioni M; Capranico G; Casazza AM; Caserini C; Cipollone A; De Cesare M; Franciotti M; Lombardi P; Madami A; Manzini S; Monteagudo E; Polizzi D; Pratesi G; Righetti SC; Salvatore C; Supino R; Zunino F
J Natl Cancer Inst; 1997 Aug; 89(16):1217-23. PubMed ID: 9274917
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
[TBL] [Abstract][Full Text] [Related]
18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
19. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
Yoshinari T; Matsumoto M; Arakawa H; Okada H; Noguchi K; Suda H; Okura A; Nishimura S
Cancer Res; 1995 Mar; 55(6):1310-5. PubMed ID: 7882328
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
